Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) (NCT06087835)
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Who can join: Review the eligibility criteria below.
Location: Research Site — Huntsville, Alabama
Age range: 18 Years to 95 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (296 Sites)
Showing the first 25 of 296 sites.
- Research Site — Huntsville, Alabama
- Research Site — Sun City West, Arizona
- Research Site — Bakersfield, California
- Research Site — Huntington Park, California
- Research Site — Los Alamitos, California
- Research Site — Los Angeles, California
- Research Site — Northridge, California
- Research Site — Oxnard, California
- Research Site — San Carlos, California
- Research Site — San Dimas, California
- Research Site — Tarzana, California
- Research Site — Victorville, California
- Research Site — Arvada, Colorado
- Research Site — Denver, Colorado
- Research Site — Boynton Beach, Florida
- Research Site — Hialeah, Florida
- Research Site — Hollywood, Florida
- Research Site — Jacksonville, Florida
- Research Site — Jensen Beach, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Orlando, Florida
- Research Site — Fayetteville, Georgia
- Research Site — Champaign, Illinois
- Research Site — Chicago, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Chronic Kidney Disease With High Proteinuria clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.